Analysis of Medicine:Current understandings about post-traumatic epilepsy


Image by jcomp on Freepik

Traumatic injuries exact a toll on societal well-being, extending beyond immediate physical consequences to encompass profound impacts on productivity and quality of life.[1] While conditions like cancer and cardiovascular disease often dominate public health discourse, traumatic brain injury (TBI) quietly ranks among the most devastating health challenges worldwide. With an estimated 55 million people affected globally, TBI not only claims lives but also leaves countless individuals grappling with long-term disabilities.[2]

Within the spectrum of TBI's repercussions, post-traumatic epilepsy (PTE) emerges as a particularly insidious sequelae. Beyond the initial trauma, PTE inflicts a secondary assault on the brain, characterized by recurrent seizures. These seizures not only exacerbate existing neurodegenerative processes but also trigger inflammation and disrupt the delicate balance of the blood-brain barrier, further impeding recovery and exacerbating disability.[3] PTE's impact extends far beyond the physical realm, profoundly affecting neurological function, emotional well-being, and occupational capacity in those affected.

The risk of PTE primarily stems from the severity of the initial injury, often gauged by the Glasgow Coma Scale (GCS) and other indicators of brain damage. However, the GCS's limitations in assessing injury severity highlight the complexity of predicting outcomes following TBI.[4] While age inversely correlates with PTE risk, with younger adults exhibiting higher susceptibility, the relationship between age and injury severity complicates the interpretation. Numerous markers of injury severity, such as decompressive craniectomy and the presence of focal injuries, contribute to increased PTE risk, although the causative mechanisms remain multifaceted and challenging to quantify. Notably, focal injuries, including cortical and subcortical contusions, significantly elevate PTE risk, with lesion size and location influencing susceptibility. In addition to focal injuries, diffuse axonal injury and secondary brain insults, such as intracranial infections and repeated TBIs, further exacerbate PTE risk, underscoring the intricate interplay of various factors in epilepsy development post-TBI.[5, 6]

Understanding PTE latency, the time from injury to the onset of seizures, remains a critical yet elusive aspect of epilepsy research. While PTE often manifests within the first few months to a year post-injury, the risk factors influencing latency, including age, injury severity, and residual disability, warrant further investigation. Subpopulations of individuals with PTE, particularly those stratified by gender, socioeconomic status, and social support networks, necessitate comprehensive study to elucidate disparities in risk and recurrence rates.[7] Despite advancements, detailed exploration of risk factors for seizure recurrence and their modulation, such as cerebrospinal fluid shunting, remains relatively understudied, highlighting avenues for future research to enhance prognostication and therapeutic strategies in PTE management.[8]

Studies have shown that PTE significantly hampers neurological recovery post-TBI and independently correlates with poorer functional outcomes. In severe TBI cases, up to one-third of individuals may develop PTE, making it a pervasive and significant concern within the broader landscape of structural epilepsies. Addressing PTE effectively thus presents a vital opportunity to alleviate the burden of disability experienced by TBI survivors and improve overall quality of life.

Epileptogenesis, the process through which PTE develops, unfolds as a complex and protracted journey within the brain. It begins with the initial insult, typically TBI, which sets in motion a cascade of events leading to abnormal electrical activity. Over months to years, epileptic circuits gradually mature during a latency period, eventually culminating in the symptomatic phase characterized by spontaneous seizures. However, the impact of epileptogenesis doesn't end there. Even after epilepsy develops, the process continues, with seizures perpetuating and expanding epileptic circuits, potentially leading to drug-resistant epilepsy.

Despite significant strides in pharmacotherapy, with the development of over 30 anti-seizure medications (ASMs) in recent decades, the underlying process of epileptogenesis remains stubbornly resistant to intervention.[9] This gap underscores the critical need for disease-modifying anti-epileptogenic medications (AEMs) capable of altering the trajectory of epilepsy development.[10] Recognizing the urgency of this challenge, numerous national and international organizations, including the World Health Organization (WHO) and the National Institutes of Health (NIH), have prioritized the development of AEMs as a public health imperative.

PTE presents a unique opportunity for advancing our understanding of epileptogenesis and exploring potential AEMs. Its well-defined trigger (TBI) and relatively short latency period make it an ideal model for studying the mechanisms underlying epilepsy development. Additionally, individuals with PTE exhibit higher rates of drug resistance compared to other epilepsy types, further highlighting the need for targeted interventions. Collaborative efforts among research consortia are actively underway to establish clinical and preclinical trial networks aimed at identifying and validating promising therapeutic targets for PTE.[11, 12]

By delving into the intricate mechanisms of PTE and epileptogenesis, we can not only enhance our understanding of these conditions but also pave the way for more effective treatments that alleviate suffering and improve outcomes for TBI survivors.


1. Pease, M., et al., Insights into epileptogenesis from post-traumatic epilepsy. Nat Rev Neurol, 2024.

2. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2019. 18(1): p. 56-87.

3. Sharma, R., et al., Neuroinflammation in Post-Traumatic Epilepsy: Pathophysiology and Tractable Therapeutic Targets. Brain Sci, 2019. 9(11).

4. Eagle, S.R., et al., Prognostic Models for Traumatic Brain Injury Have Good Discrimination but Poor Overall Model Performance for Predicting Mortality and Unfavorable Outcomes. Neurosurgery, 2023. 92(1): p. 137-143.

5. Pease, M., et al., Risk Factors and Incidence of Epilepsy after Severe Traumatic Brain Injury. Ann Neurol, 2022. 92(4): p. 663-669.

6. Arefan, D., et al., Comparison of machine learning models to predict long-term outcomes after severe traumatic brain injury. Neurosurg Focus, 2023. 54(6): p. E14.

7. Lolk, K., J.W. Dreier, and J. Christensen, Repeated traumatic brain injury and risk of epilepsy: a Danish nationwide cohort study. Brain, 2021. 144(3): p. 875-884.

8. DeGrauw, X., et al., Epidemiology of traumatic brain injury-associated epilepsy and early use of anti-epilepsy drugs: An analysis of insurance claims data, 2004-2014. Epilepsy Res, 2018. 146: p. 41-49.

9. Löscher, W., et al., Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev, 2020. 72(3): p. 606-638.

10. French, J.A., et al., Antiepileptogenesis and disease modification: Clinical and regulatory issues. Epilepsia Open, 2021. 6(3): p. 483-492.

11. Saletti, P.G., et al., Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam. Epilepsia Open, 2023. 8(2): p. 586-608.

12. Candy, N., et al., The use of antiepileptic medication in early post traumatic seizure prophylaxis at a single institution. J Clin Neurosci, 2019. 69: p. 198-205.